The strategy charges fees in line with its similarly distributed peers, priced within the middle quintile.
Janus Henderson Global Life Sciences D JNGLX
- NAV / 1-Day Return 74.34 / −0.38 %
- Total Assets 5.1 Bil
-
Adj. Expense Ratio
- Expense Ratio 0.800%
- Distribution Fee Level Below Average
- Share Class Type No Load
- Category Health
- Investment Style Large Growth
- Min. Initial Investment 2,500
- Status Limited
- TTM Yield 0.12%
- Turnover 34%
USD | NAV as of May 17, 2024 | 1-Day Return as of May 17, 2024, 11:32 PM GMT+0
Morningstar’s Analysis JNGLX
Will JNGLX outperform in future?
Get our overall rating based on a fundamental assessment of the pillars below.
People Pillar
Parent Pillar
- Current Portfolio Date
- Equity Holdings —
- Bond Holdings —
- Other Holdings —
- % Assets in Top 10 Holdings 38.0
Top 10 Holdings
|
% Portfolio Weight
|
Market Value USD
|
Sector
|
---|---|---|---|
Eli Lilly and Co | 7.06 | 379.0 Mil | Healthcare |
UnitedHealth Group Inc | 5.85 | 313.7 Mil | Healthcare |
Novo Nordisk A/S Class B | 5.18 | 277.7 Mil | Healthcare |
Merck & Co Inc | 3.63 | 194.8 Mil | Healthcare |
AstraZeneca PLC | 3.57 | 191.9 Mil | Healthcare |
AbbVie Inc | 3.36 | 180.2 Mil | Healthcare |
Sanofi SA | 2.49 | 133.7 Mil | Healthcare |
Boston Scientific Corp | 2.31 | 123.8 Mil | Healthcare |
Vertex Pharmaceuticals Inc | 2.30 | 123.5 Mil | Healthcare |
Abbott Laboratories | 2.27 | 121.6 Mil | Healthcare |